Single-chain antibodies as new antithrombotic drugs

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 2, 2007, Pages 185-195

  Hagemeyer, Christoph E ^a   Schwarz, Meike ^b   Peter, Karlheinz ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antibody fragments; Glycoprotein (GP) IIb IIIa; Hybridoma; Phage display; Thrombosis

Indexed keywords

ANTIBODY CONJUGATE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; COMPLEMENTARY DNA; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HIRUDIN; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; RECOMBINANT PLASMINOGEN ACTIVATOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SODIUM CHLORIDE; TIROFIBAN;

ANTIBODY PRODUCTION; ANTIGEN BINDING; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DRUG APPROVAL; HUMAN; INFECTION; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; VACCINE PRODUCTION;

ANTIBODIES; BLOOD PLATELETS; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; RECOMBINANT PROTEINS;

EID: 33947217524     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-969033     Document Type: Review

References (53)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256: 495-497
2. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-1078
3. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312:643-646
4. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327
5. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240: 1038-1041
6. Toleikis L, Broders O, Dubel S. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods Mol Med 2004;94:447-458
7. Kipriyanov SM, Moldenhauer G, Schuhmacher J, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999;293: 41-56
8. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-1136
9. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-545
10. Kipriyanov SM, Le Gall F. Generation and production of engineered antibodies. Mol Biotechnol 2004;26:39-60
11. Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 2001;18:31-40
12. Hayden MS, Linsley PS, Gayle MA, et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994;1:3-15
13. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001;248:47-66
14. Simmons LC, Reilly D, Klimowski L, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002;263:133-147
15. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357
16. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248:67-76
17. Chowdhury PS, Wu H. Tailor-made antibody therapeutics. Methods 2005;36:11-24
18. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-1116
19. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427-443
20. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28
21. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005;23:1117-1125
22. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994;368:856-859
23. Jostock T, Dubel S. Screening of molecular repertoires by microbial surface display. Comb Chem High Throughput Screen 2005;8:127-133
24. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-554
25. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA. Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotechnol 2001;12:361-370
26. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004;22:1161-1165
27. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983;222:1129-1132
28. Holvoet P, Laroche Y, Stassen JM, et al. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators' consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood 1993;81:696-703
29. Peter K, Graeber J, Kipriyanov S, et al. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 2000;101:1158-1164
30. Bode C, Hanson SR, Schmedtje JF Jr, et al. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation 1997;95:800-804
31. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-552
32. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation 1998;97:681-685
33. Loscalzo J. Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives. Circulation 1996;94:863-865
34. Hagemeyer CE, Tomic I, Jaminet P, et al. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 2004;92:47-53
35. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996;88:3432-3445
36. Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther 2001;296:567-572
37. Zoldhelyi P, Bichler J, Owen WG, et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994;90:2671-2678
38. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996;7:39-48
39. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593-596
40. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85:805-815
41. Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation 2003;107:2533-2537
42. Dewerchin M, Vandamme AM, Holvoet P, et al. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Thromb Haemost 1992; 68:170-179
43. Hagemeyer CE, Tomic I, Weirich U, et al. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost 2004;2: 797-803
44. Liu ZH, Wan HY, Wang B, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator composed of a humanized monoclonal antibody against activated human platelets and a single-chain urokinase. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 1998;30:601-606
45. Bi Q, Cen X, Huang Y, Zhu S. Construction and characterization of trifunctional single-chain urokinase-type plasminogen activators. Eur J Biochem 2002;269:1708-1713
46. Ding FX, Yan HL, Lu YM, et al. Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide. J Biotechnol 2006;126:394-405
47. Ding BS, Gottstein C, Grunow A, et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005;106:4191-4198
48. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-211
49. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92:3240-3249
50. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003;23:945-952
51. Schwarz M, Rottgen P, Takada Y, et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J 2004; 18:1704-1706
52. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002;99:3540-3546
53. Schwarz M, Meade G, Stoll P, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006;99:25-33